Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Mahaffey

Showing results (271-280 of 627) with videos related to

Pageof 63
Sort By:
American Heart Journal|May 16, 2016
Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trialJeffrey S Berger, Brian G Katona, W Schuyler Jones, et al.
The New England Journal of Medicine|June 28, 2002
Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunctionRonnier J Aviles, Arman T Askari, Bertil Lindahl, et al.
Diabetologia|August 27, 2021
Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA<sub>1c</sub>, disease duration and treatment intensity: results from the CANVAS ProgramTamara K Young, Jing-Wei Li, Amy Kang, et al.
The American Journal of Medicine|December 6, 2003
Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromesJohn H Alexander, Robert A Harrington, Manju Bhapkar, et al.
Circulation. Genomic and Precision Medicine|April 11, 2023
Accelerated Epigenetic Aging Is Associated With Multiple Cardiometabolic, Hematologic, and Renal Abnormalities: A Project Baseline Health SubstudyBest Uchehara, Lydia Coulter Kwee, Jessica Regan, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 14, 2025
SGLT2 Inhibition and Hospitalizations in Patients with CKD: A Meta-Analysis of Kidney Outcome TrialsMegumi Oshima, Luke Buizen, Niels Jongs, et al.
Journal of the American Heart Association|January 19, 2024
Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE TrialAbhinav Sharma, Amir Razaghizad, Abdulaziz Joury, et al.
The American Journal of Cardiology|January 31, 2007
Racial differences among high-risk patients presenting with non-ST-segment elevation acute coronary syndromes (results from the SYNERGY trial)Melvin R Echols, Kenneth W Mahaffey, Anindita Banerjee, et al.
American Heart Journal|March 21, 2016
Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation RegistryHarsh Golwala, Larry R Jackson, DaJuanicia N Simon, et al.
Journal of the American College of Cardiology|February 6, 1999
Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-IIB E Tardiff, R M Califf, J E Tcheng, et al.
Pageof 63

Showing results (271-280 of 627) with videos related to

Sort By:
Pageof 63
American Heart Journal|May 16, 2016
Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trialJeffrey S Berger, Brian G Katona, W Schuyler Jones, et al.
The New England Journal of Medicine|June 28, 2002
Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunctionRonnier J Aviles, Arman T Askari, Bertil Lindahl, et al.
Diabetologia|August 27, 2021
Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA<sub>1c</sub>, disease duration and treatment intensity: results from the CANVAS ProgramTamara K Young, Jing-Wei Li, Amy Kang, et al.
The American Journal of Medicine|December 6, 2003
Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromesJohn H Alexander, Robert A Harrington, Manju Bhapkar, et al.
Circulation. Genomic and Precision Medicine|April 11, 2023
Accelerated Epigenetic Aging Is Associated With Multiple Cardiometabolic, Hematologic, and Renal Abnormalities: A Project Baseline Health SubstudyBest Uchehara, Lydia Coulter Kwee, Jessica Regan, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 14, 2025
SGLT2 Inhibition and Hospitalizations in Patients with CKD: A Meta-Analysis of Kidney Outcome TrialsMegumi Oshima, Luke Buizen, Niels Jongs, et al.
Journal of the American Heart Association|January 19, 2024
Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE TrialAbhinav Sharma, Amir Razaghizad, Abdulaziz Joury, et al.
The American Journal of Cardiology|January 31, 2007
Racial differences among high-risk patients presenting with non-ST-segment elevation acute coronary syndromes (results from the SYNERGY trial)Melvin R Echols, Kenneth W Mahaffey, Anindita Banerjee, et al.
American Heart Journal|March 21, 2016
Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation RegistryHarsh Golwala, Larry R Jackson, DaJuanicia N Simon, et al.
Journal of the American College of Cardiology|February 6, 1999
Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-IIB E Tardiff, R M Califf, J E Tcheng, et al.
Pageof 63